Project Mercury was launched to rethink the treatment of Benign Prostatic Hyperplasia (BPH), offering a simple office-based treatment option for patients who need immediate relief from lower urinary tract symptoms (LUTS) with minimal side effects and preserving sexual function.
Around 50% of men aged 50 and above experience LUTS attributable to BPH. In men over 80 years old, this rises to over 80%. Symptoms include increased frequency of urination, nocturia, hesitancy, urgency, and weak urinary stream.
Current BPH treatment methods are associated with a multitude of side effects including sexual dysfunction. Treatment with medication is commonly linked to several potential negative side effects such as dizziness, hypertension, erectile dysfunction, and incomplete symptom relief. Surgical treatment options, including the gold standard transurethral resection of the prostate (TURP) or laser surgery, can offer permanent symptom relief, but may lead to irreparable damage to sexual function.
Project Mercury is developing an expandable structure that is placed in the prostatic urethra. It widens the narrowed prostatic urethra tissue creating an open urethral lumen for normal urinary flow. This structure is deployed using a flexible cystoscope in clinics and physicians’ offices.
Project Mercury completed preclinical studies and is preparing for clinical studies. Key opinion leaders (KOL) and physicians have commented on...
Medeon firmly believes Project Mercury represents a significant leap forward in the treatment of LUTS caused by BPH. Clinical studies and regulatory approvals are ongoing.